nach oben

International Journal of Clinical Oncology

Erschienen in:

27.02.2024 | Original Article

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer

verfasst von: Yang Li, Jun Qin, Guiming Chen, Weidong Wu, Xing Sun

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Thrombospondin-1 (THBS1) is a secretory adhesive glycoprotein involved in the progression of multiple malignancies, including breast cancer. However, the clinical significance and prognostic role of plasma THBS1 in breast cancer have yet to be clarified.

Methods

Plasma THBS1 levels in 627 breast cancer patients were analyzed by enzyme-linked immunosorbent assay. Bone marrow blood was drawn from the anterior/posterior superior iliac spine to detect the presence of disseminated tumor cells (DTCs). The effects of plasma THBS1 on the clinicopathological characteristics and survival prediction of breast cancer patients were explored.

Results

Plasma THBS1 did not correlate with overall survival, breast cancer-specific survival (BCSS), and distant disease-free survival (DDFS) in the entire breast cancer cohort. Notably, HER2-enriched patients with high-plasma THBS1 levels had significantly shorter BCSS (P = 0.027) and DDFS (P = 0.011) than those with low levels. Multivariate analyses revealed that plasma THBS1 was an independent prognostic marker of BCSS (P = 0.026) and DDFS (P = 0.007) in HER2-enriched patients. THBS1 levels were 24% higher in positive DTC patients than in negative DTC patients (P = 0.031), and high levels were significantly associated with poor BCSS in positive DTC patients (HR 2.08, 95% CI 1.17–3.71; P = 0.019). Moreover, high-plasma THBS1 levels were specifically associated with an increased occurrence of brain metastasis in HER2-enriched patients (P = 0.041).

Conclusion

These findings suggest that plasma THBS1 may be serving as an unfavorable prognosis predictor for HER2-enriched breast cancer and justifies the need for further research.

Nur mit Berechtigung zugänglich

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed

Achrol AS, Rennert RC, Anders C et al (2019) Brain metastases. Nat Rev Dis Primers 5:5PubMedCrossRef

Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54PubMedCrossRef

Nik-Zainal S, Morganella S (2017) Mutational signatures in breast cancer: the problem at the DNA level. Clin Cancer Res 23:2617–2629PubMedPubMedCentralCrossRef

Harrell JC, Prat A, Parker JS et al (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132:523–535PubMedCrossRef

Muth M, Engelhardt BM, Kröger N et al (2011) Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia. Ann Hematol 90:33–40PubMedCrossRef

Khaiboullina SF, Morzunov SP, St Jeor SC et al (2016) Hantavirus infection suppresses thrombospondin-1 expression in cultured endothelial cells in a strain-specific manner. Front Microbiol 7:1077PubMedPubMedCentralCrossRef

Zhou L, Picard D, Ra YS et al (2010) Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 70:8199–8210PubMedCrossRef

Yee KO, Streit M, Hawighorst T et al (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165:541–552PubMedPubMedCentralCrossRef

10.

Kazerounian S, Yee KO, Lawler J (2008) Thrombospondins in cancer. Cell Mol Life Sci 65:700–712PubMedPubMedCentralCrossRef

11.

Martin-Manso G, Galli S, Ridnour LA et al (2008) Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 68:7090–7099PubMedPubMedCentralCrossRef

12.

Incardona F, Lewalle JM, Morandi V et al (1995) Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 55:166–173PubMed

13.

Perez-Janices N, Blanco-Luquin I, Tuñón MT et al (2015) EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget 6:368–380PubMedPubMedCentralCrossRef

14.

Borsotti P, Ghilardi C, Ostano P et al (2015) Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. Pigment Cell Melanoma Res 28:73–81PubMedCrossRef

15.

Lyu T, Jia N, Wang J et al (2013) Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8:1330–1346PubMedPubMedCentralCrossRef

16.

Nie S, Lo A, Wu J et al (2014) Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res 13:1873–1884PubMedPubMedCentralCrossRef

17.

Ioachim E, Damala K, Tsanou E et al (2012) Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. Histol Histopathol 27:209–216PubMed

18.

Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K et al (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504–6511PubMed

19.

Mo D, He F, Zheng J et al (2021) tRNA-derived fragment tRF-17-79MP9PP attenuates cell invasion and migration via THBS1/TGF-β1/Smad3 axis in breast cancer. Front Oncol 11:656078PubMedPubMedCentralCrossRef

20.

Wang T, Srivastava S, Hartman M et al (2016) High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget 7:55155–55168PubMedPubMedCentralCrossRef

21.

Marcheteau E, Farge T, Pérès M et al (2021) Thrombospondin-1 silencing improves lymphocyte infiltration in tumors and response to anti-PD-1 in triple-negative breast cancer. Cancers (Basel) 13:4059PubMedCrossRef

22.

Rouanne M, Adam J, Goubar A et al (2016) Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer 16:483PubMedPubMedCentralCrossRef

23.

Zhu L, Li Q, Wang X et al (2019) THBS1 is a novel serum prognostic factors of acute myeloid leukemia. Front Oncol 9:1567PubMedCrossRef

24.

Hu XY, Ling ZN, Hong LL et al (2021) Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer. J Clin Lab Anal 35:e23936PubMedPubMedCentralCrossRef

25.

Suh EJ, Kabir MH, Kang UB et al (2012) Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Exp Mol Med 44:36–44PubMedCrossRef

26.

Byrne GJ, Hayden KE, McDowell G et al (2007) Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol 31:1127–1132PubMed

27.

Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223PubMedPubMedCentralCrossRef

28.

Hayden K, Tetlow L, Byrne G et al (2000) Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann Clin Biochem 37:319–325PubMedCrossRef

29.

Sutherland DR, Anderson L, Keeney M et al (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5:213–226PubMedCrossRef

30.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404PubMedCrossRef

31.

Behrens J, Frixen U, Schipper J et al (1992) Cell adhesion in invasion and metastasis. Semin Cell Biol 3:169–178PubMedCrossRef

32.

Huang T, Sun L, Yuan X et al (2017) Thrombospondin-1 is a multifaceted player in tumor progression. Oncotarget 8:84546–84558PubMedPubMedCentralCrossRef

33.

Shen J, Cao B, Wang Y et al (2018) Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer Res 37:175PubMedPubMedCentralCrossRef

34.

Murphy-Ullrich JE, Höök M (1989) Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol 109:1309–1319PubMedCrossRef

35.

Orr AW, Pallero MA, Murphy-Ullrich JE (2002) Thrombospondin stimulates focal adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation. J Biol Chem 277:20453–20460PubMedCrossRef

36.

Cen J, Feng L, Ke H et al (2019) Exosomal thrombospondin-1 disrupts the integrity of endothelial intercellular junctions to facilitate breast cancer cell metastasis. Cancers (Basel) 11

37.

Hartkopf AD, Wallwiener M, Fehm TN et al (2015) Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. Ann Oncol 26:1155–1160PubMedCrossRef

38.

Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802PubMedCrossRef

39.

Hosseini H, Obradović MMS, Hoffmann M et al (2016) Early dissemination seeds metastasis in breast cancer. Nature 540:552–558PubMedPubMedCentralCrossRef

40.

Liu X, Jin J, Liu Y et al (2021) Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction. Int Immunopharmacol 96:107618PubMedCrossRef

41.

Ghajar CM, Peinado H, Mori H et al (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15:807–817PubMedPubMedCentralCrossRef

42.

Wen XF, Yang G, Mao W et al (2006) HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25:6986–6996PubMedCrossRef

43.

Widner DB, Park SH, Eber MR et al (2018) Interactions between disseminated tumor cells and bone marrow stromal cells regulate tumor dormancy. Curr Osteoporos Rep 16:596–602PubMedPubMedCentralCrossRef

44.

Yang G, Cai KQ, Thompson-Lanza JA et al (2004) Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279:4339–4345PubMedCrossRef

45.

del Barco BI, Nebreda AR (2012) Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 40:79–84CrossRef

46.

Wen HC, Avivar-Valderas A, Sosa MS et al (2011) p38α signaling induces anoikis and lumen formation during mammary morphogenesis. Sci Signal 4:ra34PubMedPubMedCentralCrossRef

47.

Zhao HY, Ooyama A, Yamamoto M et al (2008) Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res 68:7035–7041PubMedCrossRef

48.

Wang G, Wang J, Chang A et al (2020) Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2. Oncogene 39:7034–7050PubMedPubMedCentralCrossRef

49.

Le XF, Lammayot A, Gold D et al (2005) Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280:2092–2104PubMedCrossRef

50.

Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280PubMedCrossRef

51.

Yee KO, Connolly CM, Duquette M et al (2009) The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 114:85–96PubMedCrossRef

52.

Miller TW, Kaur S, Ivins-O’Keefe K et al (2013) Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol 32:316–324PubMedPubMedCentralCrossRef

53.

Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRef

54.

Zagar TM, Van Swearingen AE, Kaidar-Person O et al (2016) Multidisciplinary management of breast cancer brain metastases. Oncology (Williston Park) 30:923–933PubMed

55.

Wang TN, Qian X, Granick MS et al (1996) Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63:39–43PubMedCrossRef

56.

Anastasi F, Greco F, Dilillo M et al (2020) Proteomics analysis of serum small extracellular vesicles for the longitudinal study of a glioblastoma multiforme mouse model. Sci Rep 10:20498PubMedPubMedCentralCrossRef

57.

Kircher DA, Trombetti KA, Silvis MR et al (2019) AKT1(E17K) activates focal adhesion kinase and promotes melanoma brain metastasis. Mol Cancer Res 17:1787–1800PubMedPubMedCentralCrossRef

58.

Priego N, Zhu L, Monteiro C et al (2018) STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med 24:1024–1035PubMedCrossRef

59.

Chen CY, Chao YM, Lin HF et al (2020) miR-195 reduces age-related blood-brain barrier leakage caused by thrombospondin-1-mediated selective autophagy. Aging Cell 19:e13236PubMedPubMedCentralCrossRef

60.

Rege TA, Stewart J Jr, Dranka B et al (2009) Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 218:94–103PubMedPubMedCentralCrossRef

61.

Meijles DN, Sahoo S, Al Ghouleh I et al (2017) The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal 10:eaaj1784PubMedPubMedCentralCrossRef

62.

Alaoui-Jamali MA, Song DJ, Benlimame N et al (2003) Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res 63:3764–3774PubMed

63.

Hosonaga M, Saya H, Arima Y (2020) Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev 39:711–720PubMedPubMedCentralCrossRef

Titel: Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer
verfasst von: Yang Li
Jun Qin
Guiming Chen
Weidong Wu
Xing Sun
Publikationsdatum: 27.02.2024
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2024
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02472-9

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data

Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression

Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases: a systematic review and meta-analysis

Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie